Expert Family Legal Support: Chennai Divorce Lawyers
Navigating Family Legal Matters with Chennai...
Technological Innovations in Continuous Glucose Monitoring Devices
The Continuous Glucose Monitoring (CGM) market is expected to reach $31.41 billion by 2031, growing at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2031. Key factors driving this growth include the increasing prevalence of diabetes, sedentary lifestyles, the advantages of CGM over traditional glucose monitoring, and the adoption of CGM by athletes and fitness enthusiasts. Additionally, technological advancements in CGM devices, a shift toward personalized care, rising health awareness, and improved accessibility to diabetes care devices in low and middle-income countries are anticipated to create significant opportunities for market players.Download free sample report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5960
Key Market Drivers
Increasing Prevalence of Diabetes
CGMs offer continuous glucose level monitoring and relay readings to healthcare providers via smartphone apps. New product launches have enhanced diabetes management. For example, in March 2024, the FDA approved Dexcom Stelo Glucose Biosensor System by DexCom, Inc., an OTC integrated CGM for patients aged 18 and older, particularly those not on insulin or without severe hypoglycemia. Factors like obesity, poor diet, sedentary lifestyles, and genetic predispositions continue to drive demand for effective glucose monitoring. The WHO reports approximately 422 million people globally have diabetes, highlighting the critical role of continuous glucose monitoring.
Advantages of CGM Over Conventional Monitoring
CGM devices provide real-time data monitoring, trend analysis, alerts for abnormal glucose levels, enhanced diabetes management, and reduce the need for fingerstick tests. The integration of AI in CGM devices further optimizes diabetes management and lifestyle adjustments. For example, in May 2023, January, Inc. launched an AI-supported app predicting individual glucose patterns, offering recommendations on calorie intake and physical activity, and providing tips on blood glucose management. This app can be integrated with CGMs and accessed via smartphones, benefitting even non-diabetic individuals on special diets.
Continuous Glucose Monitoring Market Trends
Shift Toward Smart Devices and Advanced Healthcare with Artificial Intelligence
The integration of AI in glucose monitoring is a recent development. Smart CGM devices predict glucose level fluctuations up to 60 minutes in advance and provide additional insights for better glucose management. For instance, the Guardian Connect CGM System by Medtronic allows users to track glucose patterns on mobile devices every 5 minutes. AI integration reduces the need for manual blood glucose checks, predicting sugar levels and creating personalized diabetes management plans. In March 2024, Roche launched the AI-powered 14-day Accu-Chek SmartGuide system, predicting glucose level fluctuations.
Browse in depth: https://www.meticulousresearch.com/product/continuous-glucose-monitoring-market-5960
Continuous Glucose Monitoring Market Opportunity
Technological Advancements in CGM Devices
Technological advancements in CGMs, such as wireless connectivity, personalized glucose tracking, and AI and machine learning integration, are enhancing their popularity. Enzyme-based electrochemical sensors in CGMs provide accurate and reliable information. Wireless connectivity allows real-time glucose tracking via smartphones, and integration with insulin pumps enables insulin level adjustments based on glucose readings. Additionally, implantable CGMs, like the Eversense® E3 by Senseonics Holdings, approved by the FDA in February 2022, offer long-term glucose monitoring solutions.
Continuous Glucose Monitoring Market Analysis: Key Findings
By Component: In 2024, the Sensors Segment to Dominate the Continuous Glucose Monitoring Market
The sensors segment, accounting for over 52.4% of the market, is expected to dominate due to the preference for continuous glucose monitoring and frequent sensor replacements. Disposable sensors are replaced every 7 to 14 days, while implantable sensors last 150-180 days.
Download request sample report here: https://www.meticulousresearch.com/request-sample-report/cp_id=5960
By Age Group: In 2024, the Adults Segment to Dominate the Continuous Glucose Monitoring Market
The adult segment is projected to hold a larger market share due to the high prevalence of diabetes and sedentary lifestyles among the geriatric population. According to NIDDK, in 2021, 38.4 million people had diabetes, with 38.1 million being adults aged 18 or older. The children segment is expected to register the highest growth rate, driven by the increasing diagnosis of type 1 diabetes in children.
By End User: In 2024, the Home Care Settings Segment to Dominate the Continuous Glucose Monitoring Market
The home care settings segment, expected to account for over 82.3% of the market, is driven by the rising prevalence of diabetes, increasing health awareness, and the shift toward preventive healthcare. CGM technologies are increasingly being adopted in home care due to the shortage of healthcare professionals and growing consumer awareness of diabetes monitoring.
Geographical Analysis
In 2024, North America to Dominate the Continuous Glucose Monitoring Market
North America is expected to hold the largest market share, over 42.2%, due to high accessibility to advanced technologies, the presence of prominent manufacturers, significant R&D investments, a robust reimbursement framework, and supportive government initiatives. According to CMS, U.S. healthcare spending reached $4.5 trillion in 2022. The Asia-Pacific region is projected to register the highest CAGR of over 17.40%, driven by improving healthcare infrastructure, rising disposable income, and increased investments by major market players.
Quick buy: https://www.meticulousresearch.com/Checkout/64947495
Key Companies and Recent Developments
Leading Players
Key players in the CGM market include DexCom, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Medtronic PLC, Nemaura Medical Inc., LifeScan, Inc., Senseonics Holdings, Inc., A. Menarini Diagnostics S.r.l, Medtrum Technologies, Inc., and B. Braun SE.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post